| Colman, Peter C |
| Recruiting | 3 | 450 | Europe, RoW | Fenofibrate, Inert lactose placebo | University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc | Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies | 12/24 | 12/25 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Kwan, Patrick |
NCT05219617 / 2022-001256-42: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults |
|
|
| Recruiting | 3 | 252 | Europe, US, RoW | Carisbamate | SK Life Science, Inc., SK Life Science, Inc | Seizures, Lennox Gastaut Syndrome | 06/25 | 06/26 | | |
| Davis, Stephen |
NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units |
|
|
| Completed | 2 | 201 | Europe, RoW | Tranexamic Acid, Normal saline, 0.9%NaCl | Neuroscience Trials Australia, The Florey Institute of Neuroscience and Mental Health | Intracerebral Haemorrhage | 05/23 | 05/23 | | |
| Active, not recruiting | 1 | 28 | US | Glucagon-Like Peptide- 1 (GLP-1) infusion, GLP-1, Placebo Comparator: Saline Infusion, Saline infusion | University of Maryland, Baltimore | Type 2 Diabetes Mellitus | 09/25 | 02/26 | | |
| Recruiting | 1 | 32 | US | Epinephrine, Adrenaline, Saline infusion, Placebo | University of Maryland, Baltimore, Vanderbilt University | Diabetes Complications | 09/25 | 02/26 | | |
| Recruiting | 1 | 60 | US | Placebo Oral Tablet, Fluoxetine, DHEA, dehydroepiandrosterone, Fluoxetine and DHEA, Prozac, dehydroepiandrosterone | University of Maryland, Baltimore | Type 1 Diabetes Mellitus | 09/25 | 12/26 | | |
NCT01672255: Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) |
|
|
| Recruiting | 1 | 64 | US | Fluoxetine, Prozac, Placebo control | University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI) | Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure | 09/25 | 12/26 | | |
| Recruiting | 1 | 32 | US | Glucose clamp | University of Maryland, Baltimore, Vanderbilt University | Hypoglycemia | 09/25 | 12/26 | | |
| Withdrawn | N/A | 176 | US | SmartAlbu | University of Maryland, Baltimore | Diabetes Mellitus | 12/23 | 12/23 | | |
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment |
|
|
| Recruiting | N/A | 240 | RoW | Minimally invasive hematoma evacuation | University of Melbourne | Intra Cerebral Hemorrhage, Stroke | 12/25 | 12/26 | | |
| Withdrawn | N/A | 1500 | US | Standard of Care, University of Maryland Medical System (UMMS) Charles Regional Medical Center (CRMC) Appendix A.1. Transitional Care/Nurse Navigator Program, Policy Number: 9770-001, Enhanced Care | University of Maryland, Baltimore, University of Maryland Medical System | Patient Readmission, Pulmonary Disease, Chronic Obstructive, Heart Failure, Diabetes Mellitus Poor Control, Hypertension, Pneumonia | 09/26 | 09/26 | | |
| Anderson, Paul |
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer |
|
|
| Active, not recruiting | 3 | 501 | Europe, RoW | Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM) | University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia | Bladder Cancer | 12/24 | 12/24 | | |
NCT06351904: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy |
|
|
| Recruiting | 1 | 15 | RoW | RAG-01 | Ractigen Therapeutics. | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 06/25 | 08/25 | | |
| Recruiting | N/A | 50 | RoW | Zenflow Spring System, Spring Implant | Zenflow, Inc. | Benign Prostatic Hyperplasia | 12/22 | 05/24 | | |
VAPEUR RCT, NCT04838769: REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men |
|
|
| Active, not recruiting | N/A | 154 | Europe, RoW | REZŪM, alpha blocker and 5-alpha reductase inhibitor, Dual Drug Therapy | Boston Scientific Corporation | Benign Prostatic Hyperplasia (BPH) | 02/26 | 03/27 | | |
| Szer, Jeff |
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients |
|
|
| Recruiting | 1/2 | 50 | Europe, RoW | ADX-038, siRNA, Placebo, Saline | ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 03/26 | 09/26 | | |
NCT06524726: The International PNH Interest Group PNH Registry |
|
|
| Recruiting | N/A | 2000 | US | | International PNH Interest Group | Paroxysmal Nocturnal Hemoglobinuria | 05/29 | 05/29 | | |
| Slavin, Monica |
C-SMART, NCT04534725: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; |
|
|
| Completed | 3 | 441 | RoW | Interferon alfa, Selinexor, Lenzilumab | Peter MacCallum Cancer Centre, Australia | Cancer, Covid19, Respiratory Viral Infection | 11/22 | 04/23 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study |
|
|
| Recruiting | 3 | 274 | Europe, US, RoW | DAS181, Placebo, DAS181 COVID-19, DAS181 OL | Ansun Biopharma, Inc. | Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19 | 08/25 | 08/25 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
| Not yet recruiting | 2 | 104 | US, RoW | genotype-directed dosing with dosing software based on therapeutic drug monitoring, genotype directed with dosing software | The University of Queensland, Metro North Hospital and Health Service, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, University of Sydney, Western Sydney Local Health District, Sydney Children's Hospitals Network, Peter MacCallum Cancer Centre, Australia, University of Melbourne, Queensland Children's Hospital, Royal Adelaide Hospital, Pathology Queensland, Royal Brisbane and Women's Hospital | Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease | 06/26 | 09/26 | | |
| Enrolling by invitation | N/A | 370 | RoW | Blood sampling | Melbourne Health, Peter MacCallum Cancer Centre, Australia, Western Sydney Local Health District, Walter and Eliza Hall Institute of Medical Research, Austin Hospital, Melbourne Australia | Cytomegalovirus Infections, Haematological Malignancy, Organ or Tissue Transplant; Complications, Immune Suppression | 12/23 | 12/23 | | |
| Royse, Alistair |
| Recruiting | 4 | 9180 | RoW | Cefazolin, Water for injection | Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA) | Surgical Site Infection | 01/27 | 06/27 | | |
| Terminated | N/A | 2758 | Europe, Canada, US, RoW | | Corcym S.r.l | Aortic Valve Disease, Aortic Stenosis | 03/21 | 03/21 | | |
| Recruiting | N/A | 1440 | Europe, Canada, US, RoW | Restrictive Transfusion Strategy, Liberal transfusion strategy | Unity Health Toronto | Disorder, Heart, Postoperative, Cardiac Surgery | 12/25 | 06/26 | | |
NCT04124120: Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women |
|
|
| Recruiting | N/A | 2000 | Europe, Canada, Japan, US, RoW | Single arterial graft, Multiple arterial grafting | Weill Medical College of Cornell University, New York Presbyterian Hospital, Sunnybrook Health Sciences Centre, Cedars-Sinai Medical Center, Columbia University, Duke University | Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting | 03/30 | 03/30 | | |
| Mann, Bruce |
ACTRN12610000810011: ANZ 1002 PROSPECT - A single arm phase II study using magnetic resonance imaging (MRI) to select patients with early breast cancer for omission of post-operative radiotherapy |
|
|
| Active, not recruiting | 2 | 200 | | | Breast Cancer Trials, Breast Cancer Trials | Breast Cancer | | | | |
| Recruiting | N/A | 1500 | RoW | DCISionRT Test | PreludeDx | DCIS | 05/24 | 05/34 | | |
PROSPECTIVE, NCT06445738: Post-operative Radiotherapy Omission in Selected Patients with Early Breast Cancer Trial International VErsion |
|
|
| Not yet recruiting | N/A | 1400 | RoW | Arm A: Radiotherapy Omission, A1: Grade 1 or 2/HER2 negative; A2: Grade 3 and/or HER2 positive, Arm B: Standard Treatment | Breast Cancer Trials, Australia and New Zealand | Breast Cancer, Breast Cancer Female | 01/32 | 01/39 | | |
ACTRN12621000329864: Does Confocal Laser Endomicroscopy enable identification of positive and negative surgical margin during breast cancer surgery. |
|
|
| Recruiting | N/A | 20 | | | Optiscan Pty Ltd , Medical Device Partnering Program, Optiscan Pty Ltd | Cancer | | | | |
ACTRN12615000871549: Tissue Collection Substudy in Australia and New Zealand for the participants of ANZ 1501 POSNOC (POsitive Sentinel NOde Clearance) study. |
|
|
| Active, not recruiting | N/A | 250 | | | Breast Cancer Trials, National Health and Medical Research Council | Breast Cancer | | | | |
| Sood, Siddharth |
| Recruiting | 2 | 30 | RoW | 18F-DCFPyL | Peter MacCallum Cancer Centre, Australia | Hepatocellular Carcinoma | 03/24 | 09/24 | | |
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 134 | US, RoW | SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo | Coherus Biosciences, Inc. | Hepatocellular Carcinoma | 05/25 | 05/26 | | |
| Steinfort, Daniel |
NCT06158971: Feasibility Study of the Microwave Ablation System for Lung Tissue Ablation |
|
|
| Recruiting | N/A | 10 | RoW | Flexible Bronchoscopic Microwave Ablation | phenoMapper, LLC, NIH/NCI - Grant award number: R01CA218357 | Lung Neoplasm | 01/25 | 01/25 | | |
| Active, not recruiting | N/A | 48 | RoW | Apreo Implant Group | Apreo Health, Inc. | Emphysema or COPD | 10/24 | 04/25 | | |
| Corcoran, Niall |
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer |
|
|
| Recruiting | 2 | 30 | | | Royal Melbourne Hospital, Movember, Medical Research Future Fund | Prostate Cancer | | | | |
| Recruiting | N/A | 10000 | RoW | | Melbourne Health, Peter MacCallum Cancer Centre, Australia, Epworth Healthcare, St Vincent's Hospital, Austin Health, Barwon Health, Ballarat Health Services, Western Health, Australia | Database, Prostate Cancer, Robotic-assisted Radical Prostatectomy, Surgical Outcomes, Oncological Outcomes, Patient Reported Outcome Measures, Learning Curve | 12/50 | 12/50 | | |
| Thomas, Ben |
| Completed | 3 | 4223 | Europe, US | ABNCoV2, Comirnaty | Bavarian Nordic | COVID-19 Disease | 03/23 | 10/23 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05307822: CSD210903: A Study to Determine Subject Puffing Patterns of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Ambulatory Setting |
|
|
| Completed | N/A | 194 | US | Non-combusted cigarette variant 42001401, Non-combusted cigarette variant 42001399, Non-combusted cigarette variant 40007386, Non-combusted cigarette variant 42001402 | RAI Services Company | Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking | 11/22 | 11/22 | | |
| Hughes, Peter |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/25 | 12/26 | | |
| Furrer, Marc A |
| Enrolling by invitation | N/A | 750 | RoW | Comprehensive questionnaire | Melbourne Health | Complications; Urogenital, Postprocedural | 08/22 | 12/23 | | |
| Enrolling by invitation | N/A | 250 | RoW | | Melbourne Health | Perioperative/Postoperative Complications, Urologic Diseases | 06/23 | 12/23 | | |
| Williams, Zelda |
| Recruiting | 4 | 9180 | RoW | Cefazolin, Water for injection | Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA) | Surgical Site Infection | 01/27 | 06/27 | | |
| Baker, Rob |
| Recruiting | 4 | 9180 | RoW | Cefazolin, Water for injection | Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA) | Surgical Site Infection | 01/27 | 06/27 | | |
